Enhancing the therapeutic index of radiation in multiple myeloma

Apollina Goel; Angela Dispenzieri; Thomas E. Witzig; Stephen J. Russell

doi:10.1016/j.ddmec.2006.11.012

Enhancing the therapeutic index of radiation in multiple myeloma

Apollina Goel, Angela Dispenzieri, Thomas E. Witzig, Stephen J. Russell

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Multiple myeloma is a systemic malignancy that remains incurable with current therapy. Myeloma is highly radiosensitive, and radiation-based therapies have the potential to provide significant clinical benefit. Effective deployment of radiotherapy as a systemic modality in myeloma depends on maximizing its therapeutic index by efficiently and accurately delivering the radiation to sites of myeloma cell growth and increasing the radiosensitivity of myeloma cells relative to normal tissues. In this review, we discuss various strategies that are currently under investigation to enhance clinical benefit of radiotherapy in multiple myeloma.

Original language	English (US)
Pages (from-to)	515-522
Number of pages	8
Journal	Drug Discovery Today: Disease Mechanisms
Volume	3
Issue number	4
DOIs	https://doi.org/10.1016/j.ddmec.2006.11.012
State	Published - 2006

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1016/j.ddmec.2006.11.012

Cite this

@article{68ba4cbb60ad44f78b076a25d02793d8,

title = "Enhancing the therapeutic index of radiation in multiple myeloma",

abstract = "Multiple myeloma is a systemic malignancy that remains incurable with current therapy. Myeloma is highly radiosensitive, and radiation-based therapies have the potential to provide significant clinical benefit. Effective deployment of radiotherapy as a systemic modality in myeloma depends on maximizing its therapeutic index by efficiently and accurately delivering the radiation to sites of myeloma cell growth and increasing the radiosensitivity of myeloma cells relative to normal tissues. In this review, we discuss various strategies that are currently under investigation to enhance clinical benefit of radiotherapy in multiple myeloma.",

author = "Apollina Goel and Angela Dispenzieri and Witzig, {Thomas E.} and Russell, {Stephen J.}",

note = "Funding Information: Grant support: This study has been supported by JARI Research Foundation and grant from the National Institutes of Health (NIH; CA100634-02).",

year = "2006",

doi = "10.1016/j.ddmec.2006.11.012",

language = "English (US)",

volume = "3",

pages = "515--522",

journal = "Drug Discovery Today: Disease Mechanisms",

issn = "1740-6765",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Enhancing the therapeutic index of radiation in multiple myeloma

AU - Goel, Apollina

AU - Dispenzieri, Angela

AU - Witzig, Thomas E.

AU - Russell, Stephen J.

N1 - Funding Information: Grant support: This study has been supported by JARI Research Foundation and grant from the National Institutes of Health (NIH; CA100634-02).

PY - 2006

Y1 - 2006

N2 - Multiple myeloma is a systemic malignancy that remains incurable with current therapy. Myeloma is highly radiosensitive, and radiation-based therapies have the potential to provide significant clinical benefit. Effective deployment of radiotherapy as a systemic modality in myeloma depends on maximizing its therapeutic index by efficiently and accurately delivering the radiation to sites of myeloma cell growth and increasing the radiosensitivity of myeloma cells relative to normal tissues. In this review, we discuss various strategies that are currently under investigation to enhance clinical benefit of radiotherapy in multiple myeloma.

AB - Multiple myeloma is a systemic malignancy that remains incurable with current therapy. Myeloma is highly radiosensitive, and radiation-based therapies have the potential to provide significant clinical benefit. Effective deployment of radiotherapy as a systemic modality in myeloma depends on maximizing its therapeutic index by efficiently and accurately delivering the radiation to sites of myeloma cell growth and increasing the radiosensitivity of myeloma cells relative to normal tissues. In this review, we discuss various strategies that are currently under investigation to enhance clinical benefit of radiotherapy in multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=33847065157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847065157&partnerID=8YFLogxK

U2 - 10.1016/j.ddmec.2006.11.012

DO - 10.1016/j.ddmec.2006.11.012

M3 - Review article

AN - SCOPUS:33847065157

SN - 1740-6765

VL - 3

SP - 515

EP - 522

JO - Drug Discovery Today: Disease Mechanisms

JF - Drug Discovery Today: Disease Mechanisms

IS - 4

ER -

Enhancing the therapeutic index of radiation in multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this